Suppression of myoclonus in SCA2 by piracetam.

Abstract

We report on a 30-year-old patient with advanced cerebellar degeneration due to SCA2. He presented with severe myoclonus, which was resistant to conventional therapy and dramatically improved after administration of 12-18 gm/die piracetam. Piracetam may be considered in the treatment of refractory myoclonus in spinocerebellar degenerations.

• Authors: Anna De Rosa, Pasquale Striano, Fabrizio Barbieri, Arturo de Falco, Carlo Rinaldi, Tecla Tucci, Salvatore Striano, Alessandro Filla, Giuseppe De Michele
• Journal: Movement disorders : official journal of the Movement Disorder Society (Mov Disord) Vol. 21 Issue 1 Pg. 116-8 (Jan 2006) ISSN: 0885-3185 [Print] United States
• PMID: 16149096 (Publication Type: Case Reports, Journal Article)
• Copyright: Copyright (c) 2005 Movement Disorder Society.

Chemical References

• Ataxins
• Nerve Tissue Proteins
• Piracetam

Topics

• Adult
• Ataxia (drug therapy, genetics)
• Ataxins
• Dose-Response Relationship, Drug
• Gait Ataxia (drug therapy, genetics)
• Humans
• Infusions, Intravenous
• Male
• Myoclonus (drug therapy, genetics)
• Nerve Tissue Proteins (genetics)
• Neurologic Examination (drug effects)
• Piracetam (adverse effects, therapeutic use)
• Recurrence
• Spinocerebellar Ataxias (drug therapy, genetics)
• Substance Withdrawal Syndrome (diagnosis)
• Treatment Outcome
• Trinucleotide Repeats (genetics)